{
  "docId": "019de076-aef8-73ee-832d-fdb26bc98608",
  "docSlug": "c95c061ca7ee3d0fc69daa81d5a345ff",
  "documentTitle": "Legend Biotech | Investor Presentation Deck | 14 slides",
  "authorId": "legend-biotech",
  "authorName": "Legend Biotech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 14,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Slide 7 of a corporate presentation.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-aef8-73ee-832d-fdb26bc98608/7",
  "deckHref": "/decks/019de076-aef8-73ee-832d-fdb26bc98608",
  "deckJsonHref": "/decks/019de076-aef8-73ee-832d-fdb26bc98608.json",
  "deckAnchorHref": "/decks/019de076-aef8-73ee-832d-fdb26bc98608#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "KOL, key opinion leaders. *Legal entity to the agreement is Janssen Biotech, Inc.; collaboration established in December 2017. This presentation is for investor relations purposes only – Not for product promotional purposes",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a92bb805-921d-4e59-a272-919314d33113",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.09,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47c091c8-96cf-49a7-8dfe-d664900fcf8c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.82,
        "x": 0.15,
        "y": 0.53
      },
      "kind": "list",
      "text": "MANUFACTURING EXPERTISE DEVELOPED THROUGH GLOBAL COLLABORATION WITH J&J*: Cilta-cel development collaboration combines Legend’s leadership with J&J’s expertise; Expanding manufacturing capacity in the US, China, and EU",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c238d77-d707-41e0-898f-9a057947f192",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.82,
        "x": 0.15,
        "y": 0.15
      },
      "kind": "list",
      "text": "MARKET-LEADING MULTIPLE MYELOMA (MM) CAR-T THERAPY: sBLA and Type II variation to support label expansion accepted by U.S. FDA and EMA; Application supported by first randomized Phase 3 study for cilta-cel use as early as 2L",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14d00bb0-e8ce-49db-a7b1-1fa24d58bfda",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.82,
        "x": 0.15,
        "y": 0.31
      },
      "kind": "list",
      "text": "COMPELLING MM PROGRAM AND AN INNOVATIVE PIPELINE: Cilta-cel demonstrates consistently deep and durable responses; De-risked Phase 3 Programs; Additional pre- / early clinical stage programs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7192b692-af16-4e51-80a3-2e36041efac2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.82,
        "x": 0.15,
        "y": 0.74
      },
      "kind": "list",
      "text": "INTEGRATED CELL THERAPY PLATFORM: In-house antibody generation and CAR-T specific functional screening; Early clinical proof-of-concept; Autologous and allogeneic platforms; Strong intellectual property position",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a80bfed1-2fb0-4b81-a1fc-f8c909d7923a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.74,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "A Fully Integrated Global Leader in Cell Therapy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88e6e9a3-a38a-4848-8922-5d17371d687a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 7,
      "beatId": "977a8d4f-4df4-494e-86ca-251dca92744b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The deck presents Legend Biotech's differentiated R&D approach and global collaboration.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}